Aromasin - Exemestane produces slightly better results in postmenopausal women with breast cancer than Arimidex - Anastrazole but not significantly. Or offers to switch from Arimidex to Aromasin if that fails to catch on more opportunities than the other way. Article posted August 3, 2011
August 3, 2011: Source: Cancer. June 29 2011. doi: 10.1002/cncr.26299.
Women age after the transition with hormone sensitive advanced breast cancer may benefit from both Aromasin - exemestane as Arimidex - Anastrazole. There is little difference between efectiviteit tThis two agents. However, if one fails, the two agents switch from Arimidex - Anastrazole to Aromasin - exemestane has a reasonable chance of improvement. 7 of the 16 patients who switched had benefited them. Conversely, the chance is much less. Only 1 of the 12 who switched took advantage of it. According to a randomized phase II trial in 103 women with hormone sensitive breast cancer. Interestingly, the researchers this result already planned a phase III study with similar goals cancel. The differences are apparently not big enough for a long-term and expensive phase III study to justify. Here is the abstract of the study. studierapprot The full fee is on file at Wiley Online Library .
Exemestane no better than anastrozole in breast cancer, but switching from Arimidex to Aromasin failing Obtain a benefit in 45% of the Patients
Source: Wiley Online Library
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Source
Medical Oncology Service, Biomedical Research Institute, the Arnau Vilanova University Hospital, Lleida, Spain, Medical Oncology Service, Oncology Institute of Valencia, Valencia, Spain. allombart@arnau.scs.es.
Abstract
BACKGROUND:
Several studies have reported aromatase inhibitor variations in the inhibitory potency of agents thesis That Could lead to differences in clinical outcomes. In the current study, the authors Formally Evaluated the activity of anastrozole and exemestane in postmenopausal women with hormone-responsive, advanced breast cancer.
METHODS:
Postmenopausal women who had measurable disease, According To Response Evaluation Criteria in Solid Tumors and had not received previous endocrine therapy for advanced breast cancer were randomized to receive oral exemestane 25 mg daily Either or oral anastrozole 1 mg daily Until They had disease progression. The primary endpoint was the objective response rate (ORR) and secondary endpoints included the clinical benefit rate (CBR), time to progression (TTP), overall survival, and safety. Crossover to the other aromatase inhibitor was Permitted at the time of disease progression, ORR, CBR, and TTP after second-line treatment were Also Explored.
RESULTS:
In total, 103 patients were enrolled. The median patient age was 71.6 years, 52.4% had visceral disease or patient, or patient and 75.8% had ≥ 2 disease sites. Half of the patient had received previous tamoxifen, and 60% had received previous chemotherapy. The efficacy observed in the exemestane and anastrozole groups had an ORR of 36.2% and 46%, respectively, a CBR of 59.6% and 68%, respectively, and a TTP of 6.1 months and 12.1 months, respectively. At progression, 28 patients crossed over to the other aromatase inhibitors, include 16 patients who switched to exemestane (CBR, 43.7%, TTP 4.4 months) and 12 patients who switched to anastrozole (CBR, 8.3%, TTP, 2 months). Both drugs were well tolerated GeneRally, and no study drug-related serious adverse events were reported.
CONCLUSIONS:
In this phase 2 randomized trial, no significant differences in clinical activity were observed in favor of exemestane to justify a phase 3 superiority trial design in the first-line setting. Cancer 2011;. © 2011 American Cancer Society.
Copyright © 2011 American Cancer Society.
- PMID:
- 21717449
- [PubMed - as supplied by publisher]
